137 related articles for article (PubMed ID: 8538482)
21. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.
Harris ST; Eriksen EF; Davidson M; Ettinger MP; Moffett AH; Baylink DJ; Crusan CE; Chines AA
J Clin Endocrinol Metab; 2001 May; 86(5):1890-7. PubMed ID: 11344179
[TBL] [Abstract][Full Text] [Related]
22. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
Chesnut CH; Silverman S; Andriano K; Genant H; Gimona A; Harris S; Kiel D; LeBoff M; Maricic M; Miller P; Moniz C; Peacock M; Richardson P; Watts N; Baylink D
Am J Med; 2000 Sep; 109(4):267-76. PubMed ID: 10996576
[TBL] [Abstract][Full Text] [Related]
23. Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate.
Watts NB; Becker P
Bone; 1999 Jan; 24(1):65-8. PubMed ID: 9916786
[TBL] [Abstract][Full Text] [Related]
24. Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
Yonsei Med J; 2005 Dec; 46(6):750-8. PubMed ID: 16385649
[TBL] [Abstract][Full Text] [Related]
25. A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D.
Henriksen K; Byrjalsen I; Andersen JR; Bihlet AR; Russo LA; Alexandersen P; Valter I; Qvist P; Lau E; Riis BJ; Christiansen C; Karsdal MA;
Bone; 2016 Oct; 91():122-9. PubMed ID: 27462009
[TBL] [Abstract][Full Text] [Related]
26. Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids.
Campbell IA; Douglas JG; Francis RM; Prescott RJ; Reid DM;
Thorax; 2004 Sep; 59(9):761-8. PubMed ID: 15333852
[TBL] [Abstract][Full Text] [Related]
27. Effects of 5-year treatment with elcatonin and alfacalcidol on lumbar bone mineral density and the incidence of vertebral fractures in postmenopausal women with osteoporosis: a retrospective study.
Iwamoto J; Takeda T; Ichimura S; Uzawa M
J Orthop Sci; 2002; 7(6):637-43. PubMed ID: 12486466
[TBL] [Abstract][Full Text] [Related]
28. A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial.
Sahota O; Fowler I; Blackwell PJ; Lawson N; Cawte SA; San P; Masud T; Hosking DJ
Osteoporos Int; 2000; 11(11):959-66. PubMed ID: 11193249
[TBL] [Abstract][Full Text] [Related]
29. Prevention of early postmenopausal bone loss with cyclical etidronate.
Adami S; Bruni V; Bianchini D; Becorpi A; Lombardi P; Campagnoli C; Ferrari A; Marchesoni T; Balena R
J Endocrinol Invest; 2000 May; 23(5):310-6. PubMed ID: 10882149
[TBL] [Abstract][Full Text] [Related]
30. [Etidronate for treatment of osteoporosis].
Asano S; Suzuki A; Itoh M
Nihon Rinsho; 2009 May; 67(5):938-42. PubMed ID: 19432113
[TBL] [Abstract][Full Text] [Related]
31. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.
Chesnut CH; Majumdar S; Newitt DC; Shields A; Van Pelt J; Laschansky E; Azria M; Kriegman A; Olson M; Eriksen EF; Mindeholm L
J Bone Miner Res; 2005 Sep; 20(9):1548-61. PubMed ID: 16059627
[TBL] [Abstract][Full Text] [Related]
32. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.
Storm T; Kollerup G; Thamsborg G; Genant HK; Sørensen OH
J Rheumatol; 1996 Sep; 23(9):1560-4. PubMed ID: 8877926
[TBL] [Abstract][Full Text] [Related]
33. Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study.
Hejdova M; Palicka V; Kucera Z; Vlcek J
Pharm World Sci; 2005 Jun; 27(3):149-53. PubMed ID: 16096879
[TBL] [Abstract][Full Text] [Related]
34. Initiation of osteoporosis treatment after bone mineral density testing.
Pressman A; Forsyth B; Ettinger B; Tosteson AN
Osteoporos Int; 2001; 12(5):337-42. PubMed ID: 11444079
[TBL] [Abstract][Full Text] [Related]
35. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.
Harris ST; Watts NB; Jackson RD; Genant HK; Wasnich RD; Ross P; Miller PD; Licata AA; Chesnut CH
Am J Med; 1993 Dec; 95(6):557-67. PubMed ID: 8259772
[TBL] [Abstract][Full Text] [Related]
36. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
37. Hormone replacement therapy (HRT) or etidronate for osteoporosis in postmenopausal asthmatics on glucocorticoids: a randomised factorial trial.
Campbell IA; Douglas JG; Francis RM; Prescott RJ; Reid DM;
Scott Med J; 2009 Feb; 54(1):21-5. PubMed ID: 19291931
[TBL] [Abstract][Full Text] [Related]
38. Osteoporosis: trials and tribulations.
Seeman E
Am J Med; 1997 Aug; 103(2A):74S-87S; discussion 87S-89S. PubMed ID: 9302899
[TBL] [Abstract][Full Text] [Related]
39. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis.
Lane NE; Sanchez S; Genant HK; Jenkins DK; Arnaud CD
Osteoporos Int; 2000; 11(5):434-42. PubMed ID: 10912846
[TBL] [Abstract][Full Text] [Related]
40. Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis.
Grey AB; Cundy TF; Reid IR
Clin Endocrinol (Oxf); 1994 May; 40(5):671-7. PubMed ID: 8013147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
